AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29504499 — intervention group
Group type: COMPARATOR
Intervention: Non-quadrupling group
Number of subjects: 1871
Study 27041524 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics supplementation for 28 weeks
Number of subjects: 42
Study 27041524 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule for 28 weeks
Number of subjects: 42
Study 24450858 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib, 150 mg twice daily
Number of subjects: 125
Study 21671413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity progressive resistance training (PRT)
Number of subjects: 18
Study 21671413 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity range of movement exercise (control)
Number of subjects: 18
Study 19620898 — intervention group
Group type: EXPERIMENTAL
Intervention: No warm-up (NWU)
Number of subjects: 11
Study 19620898 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady state warm-up
Number of subjects: 11
Study 19620898 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval warm-up
Number of subjects: 11
Study 18198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR, 25% restriction)
Number of subjects: 48
Study 18198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction plus structured exercise (CR+EX, 12.5% restriction plus 12.5% increased energy expenditure via exercise)
Number of subjects: 48
Study 18198305 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD, 890 kcal/d supplement diet until 15% weight loss, then weight maintenance)
Number of subjects: 48
Study 18198305 — intervention group
Group type: COMPARATOR
Intervention: Control (weight maintenance)
Number of subjects: 48
Study 15925776 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind transpyloric placement using a specifically designed nasojejunal tube (NJT)
Number of subjects: 14
Study 15925776 — intervention group
Group type: COMPARATOR
Intervention: Standard nasogastric tube (NGT)
Number of subjects: 14
Study 12011906 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-degree head-up position with 10-degree leg elevation
Number of subjects: 10
Study 12011906 — intervention group
Group type: COMPARATOR
Intervention: Supine for 10 minutes without leg elevation alternating with 10 minutes of side-lying
Number of subjects: 10
Study 12011906 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine for 10 minutes with leg elevation at 10 degrees alternating with side-lying every 10 minutes
Number of subjects: 10
Study 9657627 — intervention group
Group type: EXPERIMENTAL
Intervention: Derapril
Number of subjects: 37
Study 9657627 — intervention group
Group type: COMPARATOR
Intervention: Manidipine
Number of subjects: 37
Study 7664860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 14
Study 7664860 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled bumetanide (2 mg)
Number of subjects: 14
Study 7664860 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral placebo + inhaled frusemide
Number of subjects: 14
Study 7664860 — intervention group
Group type: COMPARATOR
Intervention: Oral flurbiprofen
Number of subjects: 14
Study 7664860 — intervention group
Group type: COMPARATOR
Intervention: Oral flurbiprofen alone
Number of subjects: 14
Study 2651176 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin suspension, given twice daily, 40 mg/kg body weight for 10 days
Number of subjects: 97
Study 2651176 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin suspension, given three times daily, 40 mg/kg body weight for 10 days
Number of subjects: 97
Study 137987 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame
Number of subjects: 126
Study 137987 — intervention group
Group type: COMPARATOR
Intervention: Sucrose
Number of subjects: 126
Study 30883562 — intervention group
Group type: EXPERIMENTAL
Intervention: Park upkeep, presence of playground or outdoor fitness equipment
Number of subjects: 972
Study 30883562 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of sport field (soccer and basketball)
Number of subjects: 972
Study 28494884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope-guided intubation
Number of subjects: 74
Study 28494884 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope-guided intubation
Number of subjects: 74
Study 27872119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of nicorandil
Number of subjects: 50
Study 27872119 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of adenosine
Number of subjects: 50
Study 24708195 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 0
Study 22723612 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230
Study 20197236 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17403493 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally rooted, couple-focused HIV prevention program
Number of subjects: 0
Study 17050270 — intervention group
Group type: EXPERIMENTAL
Intervention: Right temporal resections (n=15)
Number of subjects: 43
Study 17050270 — intervention group
Group type: EXPERIMENTAL
Intervention: Left temporal resections (n=13)
Number of subjects: 43
Study 17050270 — intervention group
Group type: COMPARATOR
Intervention: Control participants (n=15)
Number of subjects: 43
Study 12891310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (starting dose 2.5 mg in group 1 and 5 mg in group 2, increased to 10 mg daily over 8 weeks)
Number of subjects: 30
Study 12891310 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (group 1: gradual regimen starting at 2.5 mg; group 2: more active regimen starting at 5 mg)
Number of subjects: 30
Study 10472219 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg kg‐1 i.v.
Number of subjects: 30
Study 10472219 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 8735088 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPLICOR C. trachomatis Test (urine specimens)
Number of subjects: 1238
Study 8735088 — intervention group
Group type: COMPARATOR
Intervention: Endocervical swab specimen culture
Number of subjects: 1238
Study 8735088 — intervention group
Group type: EXPERIMENTAL
Intervention: AMPLICOR C. trachomatis Test (endocervical swab specimens)
Number of subjects: 1238
Study 8735088 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine PCR
Number of subjects: 1238
Study 8735088 — intervention group
Group type: COMPARATOR
Intervention: Culture of urethral specimens
Number of subjects: 1238
Study 1670442 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with no immediate injection of enoxaparin (Group I, 65 patients)
Number of subjects: 188
Study 1670442 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia with 20 mg of enoxaparin one hour after the onset of anaesthesia (Group II, 61 patients)
Number of subjects: 188
Study 1670442 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with 40 mg of enoxaparin 12 hours prior to surgery (Group III, 62 patients)
Number of subjects: 188
Study 6405346 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbogen inhalation
Number of subjects: 0
Study 6405346 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of papaverine and low‐molecular dextran
Number of subjects: 0
Study 31468208 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 24
Study 31468208 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 24
Study 28319467 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1 g
Number of subjects: 40
Study 28319467 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 40
Study 26353833 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) + Methotrexate (MTX)
Number of subjects: 619
Study 26353833 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Methotrexate (MTX)
Number of subjects: 619
Study 23446330 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive approach (MicroHip)
Number of subjects: 134
Study 23446330 — intervention group
Group type: COMPARATOR
Intervention: Transgluteal approach
Number of subjects: 134
Study 23446330 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches (MicroHip and Transgluteal)
Number of subjects: 134
Study 22321673 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aneurysm repair (EVAR)
Number of subjects: 84
Study 22321673 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 84
Study 22321673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 19966482 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum strain HSK201
Number of subjects: 19
Study 19966482 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-fermented milk)
Number of subjects: 19
Study 17624838 — intervention group
Group type: EXPERIMENTAL
Intervention: RIX4414 vaccine
Number of subjects: 0
Study 14767020 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysis (HD)
Number of subjects: 41
Study 14767020 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (GTN)
Number of subjects: 41
Study 14767020 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta 2-agonist (salbutamol)
Number of subjects: 41
Study 11991909 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural infant sleep intervention (controlled crying)
Number of subjects: 156
Study 9602870 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcipotriol and betamethasone valerate after 2 weeks of calcipotriol monotherapy
Number of subjects: 169
Study 9602870 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol monotherapy
Number of subjects: 169
Study 7997001 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 437
Study 7997001 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-care treatment
Number of subjects: 437
Study 7997001 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home treatment after one week of day-care
Number of subjects: 437
Study 7997001 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 437
Study 2574675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramixotidine 750 mg p.o. administered at 22.00 h
Number of subjects: 11
Study 2574675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 4370512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone pips at 250 Hz
Number of subjects: 2
Study 4370512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone pips at 1000 Hz
Number of subjects: 2
Study 4370512 — intervention group
Group type: EXPERIMENTAL
Intervention: Tone pips at 4000 Hz
Number of subjects: 2
Study 4370512 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide band clicks
Number of subjects: 2
Study 4370512 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no acoustic stimuli)
Number of subjects: 2
Study 30523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining exergaming and physical therapy, 90 minutes twice a week for 12 weeks
Number of subjects: 17
Study 30523659 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid intervention combining exergaming and physical therapy
Number of subjects: 17
Study 30523659 — intervention group
Group type: COMPARATOR
Intervention: Control group (only assessment)
Number of subjects: 17
Study 28396048 — intervention group
Group type: EXPERIMENTAL
Intervention: S4 (aroma + taste)
Number of subjects: 26
Study 28396048 — intervention group
Group type: COMPARATOR
Intervention: S1 (water)
Number of subjects: 26
Study 26189039 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305
Study 26189039 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305
Study 23614897 — intervention group
Group type: EXPERIMENTAL
Intervention: FM containing 10(7) cfu LG2055/g
Number of subjects: 210
Study 23614897 — intervention group
Group type: EXPERIMENTAL
Intervention: FM containing 10(6) cfu LG2055/g
Number of subjects: 210
Study 23614897 — intervention group
Group type: COMPARATOR
Intervention: Control group (0 cfu LG2055/g)
Number of subjects: 210
Study 21889800 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (lecture, video, and classroom demonstration) promoting spectacle purchase at intervention schools.
Number of subjects: 15404
Study 21889800 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention).
Number of subjects: 15404
Study 20218087 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD (60 min)
Number of subjects: 27
Study 20218087 — intervention group
Group type: EXPERIMENTAL
Intervention: MLD (30 min) + IPC (30 min)
Number of subjects: 27
Study 17112403 — intervention group
Group type: EXPERIMENTAL
Intervention: 10000 lux light treatment and a placebo capsule
Number of subjects: 96
Study 17112403 — intervention group
Group type: COMPARATOR
Intervention: 100 lux light treatment (placebo light) and 20 mg fluoxetine
Number of subjects: 96
Study 14670810 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg orally 4 times daily)
Number of subjects: 10
Study 14670810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 14670810 — intervention group
Group type: COMPARATOR
Intervention: Lean controls (historical control group)
Number of subjects: 10
Study 11578293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous crystalloid based on body-weight (group 2)
Number of subjects: 41
Study 11578293 — intervention group
Group type: COMPARATOR
Intervention: No intravenous fluid (group 1)
Number of subjects: 41
Study 9631992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 150 mg
Number of subjects: 151
Study 9631992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 300 mg
Number of subjects: 151
Study 9631992 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 450 mg
Number of subjects: 151
Study 9631992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 8073312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education intervention for chronic back pain
Number of subjects: 13
Study 8073312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education intervention for acute back pain (including work-site visits)
Number of subjects: 13
Study 8073312 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education intervention (various studies)
Number of subjects: 13
Study 2146875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (2 g/kg/month)
Number of subjects: 49
Study 2146875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2146875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin
Number of subjects: 49
Study 56589 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin (growth-hormone release-inhibiting hormone)
Number of subjects: 0
Study 56589 — intervention group
Group type: COMPARATOR
Intervention: Frusemide
Number of subjects: 0
Study 31169572 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation
Number of subjects: 140
Study 31169572 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 140
Study 28157691 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 39
Study 28157691 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidiol
Number of subjects: 39
Study 28157691 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alfacalcidiol and metformin
Number of subjects: 39
Study 28157691 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D therapy
Number of subjects: 39
Study 25921346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) using various ablation technologies (duty-cycled phased RF multipolar ablation with PVAC, cooled-tip RF ablation, cryoballoon ablation)
Number of subjects: 52
Study 25921346 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased RF (PVAC)
Number of subjects: 52
Study 25921346 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigated RF
Number of subjects: 52
Study 25921346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 52
Study 24118062 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg/day)
Number of subjects: 1228
Study 24118062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 21329776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (i.d.) vaccination (2 μg/dose)
Number of subjects: 80
Study 21329776 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (i.m.) vaccination (10 μg/dose)
Number of subjects: 80
Study 19192457 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 31
Study 19192457 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lithium and divalproex
Number of subjects: 31
Study 17339642 — intervention group
Group type: COMPARATOR
Intervention: Normal psychomotor activity
Number of subjects: 457
Study 17339642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoactive psychomotor activity
Number of subjects: 457
Study 17339642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperactive psychomotor activity
Number of subjects: 457
Study 17339642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed psychomotor activity
Number of subjects: 457
Study 15754692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobe-isthmusectomy
Number of subjects: 80
Study 15754692 — intervention group
Group type: COMPARATOR
Intervention: Total thyroidectomy
Number of subjects: 80
Study 11101487 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (20 g powder/d)
Number of subjects: 96
Study 11101487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 8832535 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of dexamethasone (DEX)
Number of subjects: 14
Study 8832535 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of hydrocortisone (HCO)
Number of subjects: 14
Study 8832535 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 14
Study 1561270 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibrin adhesive used to seal split-thickness skin grafts
Number of subjects: 7
Study 1561270 — intervention group
Group type: COMPARATOR
Intervention: No adhesive used (control)
Number of subjects: 7
Study 1561270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both sealed and unsealed grafts
Number of subjects: 7
Study 6321455 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin (188 mg/day)
Number of subjects: 36
Study 6321455 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (173 mg/day)
Number of subjects: 36
Study 30357468 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 131
Study 30357468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy (HT)
Number of subjects: 131
Study 30357468 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 131
Study 30572837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg tramadol
Number of subjects: 90
Study 30572837 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg tramadol
Number of subjects: 90
Study 30572837 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study 26811430 — intervention group
Group type: EXPERIMENTAL
Intervention: artesunate + sulfadoxine-pyrimethamine (AS+SP)
Number of subjects: 0
Study 26811430 — intervention group
Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 0
Study 24931567 — intervention group
Group type: EXPERIMENTAL
Intervention: MSDC-0160 (150 mg once daily)
Number of subjects: 29
Study 24931567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 22818063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg (T20 mg)
Number of subjects: 357
Study 22818063 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 40 mg (T40 mg)
Number of subjects: 357
Study 19439084 — intervention group
Group type: EXPERIMENTAL
Intervention: RTW‐E programme
Number of subjects: 200
Study 19439084 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 200
Study 17311545 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 20
Study 17311545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GH replacement therapy)
Number of subjects: 20
Study 15140122 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive screening for occult cancer
Number of subjects: 201
Study 15140122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further testing)
Number of subjects: 201
Study 11782331 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl (1 microg/mL) combined with Lidocaine 0.4% (F-L Group)
Number of subjects: 30
Study 11782331 — intervention group
Group type: COMPARATOR
Intervention: Epidural Morphine (20 microg/kg bolus every eight hours) (M Group)
Number of subjects: 30
Study 11782331 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Fentanyl with Lidocaine infusion
Number of subjects: 30
Study 11782331 — intervention group
Group type: COMPARATOR
Intervention: Epidural Morphine
Number of subjects: 30
Study 10354692 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to copper (mean concentration below 0.05 mg x m‐3)
Number of subjects: 267
Study 10354692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to copper)
Number of subjects: 267
Study 8131523 — intervention group
Group type: EXPERIMENTAL
Intervention: Eucapnic voluntary hyperventilation (EVH)
Number of subjects: 16
Study 8131523 — intervention group
Group type: COMPARATOR
Intervention: Methacholine inhalation challenge (MIC)
Number of subjects: 16
Study 2632113 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-erythrocyte aggregation (troxerutin)
Number of subjects: 64
Study 2632113 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched for age, sex, risk factors, and vascular disease)
Number of subjects: 64
Study 1194144 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory elastic load (12.1 cmH2O/l)
Number of subjects: 7